West Pharmaceutical Services Inc. Stock
West Pharmaceutical Services Inc. shows a slight decrease today, losing -€1.100 (-0.450%) compared to yesterday.
West Pharmaceutical Services Inc. is currently one of the favorites of our community with 14 Buy predictions and no Sell predictions.
With a target price of 299 € there is a positive potential of 24.27% for West Pharmaceutical Services Inc. compared to the current price of 240.6 €.
Pros and Cons of West Pharmaceutical Services Inc. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of West Pharmaceutical Services Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| West Pharmaceutical Services Inc. | -0.450% | 0.712% | -2.512% | -20.013% | -24.411% | 5.318% | 7.411% |
| Icu Medical Inc. | -0.820% | -4.724% | 9.009% | -17.123% | -17.687% | -20.395% | -24.845% |
| Bio-Rad Labs Inc. A | 0.330% | -4.419% | 1.365% | -14.689% | -12.544% | -30.928% | -40.541% |
| Neogen Corp. | 0.980% | -0.962% | -2.830% | -59.127% | -57.083% | - | - |
Comments
West Pharmaceutical Services (NYSE:WST) is now covered by analysts at TD Cowen. They set a "buy" rating and a $350.00 price target on the stock.
Show more
Ratings data for WST provided by MarketBeat
West Pharmaceutical Services (NYSE:WST) was given a new $345.00 price target on by analysts at Deutsche Bank Aktiengesellschaft. They now have a "buy" rating on the stock.
Show more
Ratings data for WST provided by MarketBeat
West Pharmaceutical Services (NYSE:WST) had its price target raised by analysts at KeyCorp from $325.00 to $350.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for WST provided by MarketBeat
News
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceuticals
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) and reminds
